Discourage Using PPIs With New Hep C Med Epclusa

September 2016

Please see the October 2016 FDA advisory about the risk of Hepatitis B reactivation in some patients being treated for Hepatitis C.

New once-daily Epclusa (ep-KLOO-suh, sofosbuvir/velpatasvir) will further simplify outpatient hepatitis C treatment.

Epclusa seems to work as well as other recent hep C meds...can be used for ANY hep C genotype...and patients use just a 12-week course.

But most hep C medications probably won't be on your hospital's formulary due to cost and procurement issues. Epclusa will cost about $75,000 per course...compared to about $55,000 for Zepatier and about $95,000 for Harvoni.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote